{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:04:32Z","timestamp":1760101472397,"version":"3.37.3"},"reference-count":58,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Olmesartan, originally known for its antihypertensive properties, exhibits\n                    promising potential in addressing inflammation-mediated diseases. As an\n                    angiotensin II receptor blocker (ARB), Olmesartan influences pivotal pathways,\n                    including reactive oxygen species, cytokines, NF-\u03baB, TNF-\u03b1, and\n                    MAPK. This suggests a viable opportunity for repurposing the drug in conditions\n                    such as ulcerative colitis, neuropathy, nephropathy, and cancer, as supported by\n                    multiple preclinical studies. Ongoing clinical trials, particularly in\n                    cardiomyopathy and nephropathy, suggest a broader therapeutic scope for\n                    Olmesartan. Repurposing efforts would entail comprehensive investigations using\n                    disease-specific preclinical models and dedicated clinical studies. The\n                    drug\u2019s established safety profile, wide availability, and\n                    well-understood ARB mechanism of action offer distinct advantages that could\n                    facilitate a streamlined repurposing process. In summary, Olmesartan\u2019s\n                    versatile impact on inflammation-related pathways positions it as a promising\n                    candidate for repurposing across various diseases. Ongoing clinical trials and\n                    the drug\u2019s favorable attributes enhance its appeal for further\n                    exploration and potential application in diverse medical contexts.<\/jats:p>","DOI":"10.1055\/a-2244-3136","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:27:30Z","timestamp":1707870450000},"page":"93-101","source":"Crossref","is-referenced-by-count":3,"title":["From Hypertension to Beyond: Unraveling the Diverse Mechanisms of\n                    Olmesartan in Disease Modulation"],"prefix":"10.1055","volume":"74","author":[{"given":"Laiba","family":"Rind","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Integral University,\n                    Lucknow, India"},{"name":"Department of Pharmacology, Era College of Pharmacy, Era University,\n                    Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-2594","authenticated-orcid":false,"given":"Tarique","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Integral University,\n                    Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Haris","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Faculty of Engineering, Integral\n                    University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9613-2873","authenticated-orcid":false,"given":"Farogh","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Integral University,\n                    Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshiya","family":"Shamim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Integral University,\n                    Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamir","family":"Anwar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Integral University,\n                    Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajnish Kumar","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Era College of Pharmacy, Era University,\n                    Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.colsurfb.2018.02.011","article-title":"Solid lipid nanoparticles as an efficient drug delivery system of olmesartan\n                    medoxomil for the treatment of hypertension","volume":"165","author":"N T Pandya","year":"2018","journal-title":"Colloids and surf. B: Biointerfaces"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.dld.2013.12.014","article-title":"Five cases of sprue-like enteropathy in patients treated by olmesartan","volume":"46","author":"H Th\u00e9ophile","year":"2014","journal-title":"Dig Liver Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41440-017-0008-y","article-title":"Hypertension with diabetes mellitus complications","volume":"41","author":"D Yamazaki","year":"2018","journal-title":"Hypertens Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/vhrm.2006.2.4.327","article-title":"Olmesartan medoxomil: current status of its use in monotherapy","volume":"2","author":"H R Brunner","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e12471","DOI":"10.1111\/1755-5922.12471","article-title":"Management of arterial hypertension with angiotensin receptor blockers: Current\n                    evidence and the role of olmesartan","volume":"36","author":"S Omboni","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/HJH.0b013e32835d2b05","article-title":"Olmesartan-based therapies: an effective way to improve blood pressure control\n                    and cardiovascular protection","volume":"31","author":"A de la Sierra","year":"2013","journal-title":"J. Hyperten"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1524-6175.2001.01136.x","article-title":"Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the\n                    control of essential hypertension","volume":"3","author":"S Oparil","year":"2001","journal-title":"The J Clin Hypertens"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00004872-200106001-00005","article-title":"Olmesartan medoxomil: influence of age, renal and hepatic function on the\n                    pharmacokinetics of olmesartan medoxomil","volume":"19","author":"K von Bergmann","year":"2001","journal-title":"J Hypertens"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2165\/00003088-200544120-00011","article-title":"Population Pharmacokinetics of Olmesartan Following Oral Administration of its\n                    Prodrug, Olmesartan Medoxomil","volume":"44","author":"K Yoshihara","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cpdd.1086","article-title":"Pharmacokinetics and Bioequivalence Evaluation of 2 Olmesartan Medoxomil and\n                    Amlodipine Besylate Fixed-Dose Combination Tablets in Healthy Chinese Volunteers\n                    Under Fasting and Fed Conditions","volume":"11","author":"X Li","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"117181","DOI":"10.1016\/j.lfs.2019.117181","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as\n                    therapeutic options in the treatment of renal cancer: A meta-analysis","volume":"242","author":"F Asgharzadeh","year":"2020","journal-title":"Life sci"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1139\/cjpp-2019-0299","article-title":"Protective effects of olmesartan and l-carnitine on doxorubicin-induced\n                    cardiotoxicity in rats. Can","volume":"98","author":"M M Aziz","year":"2020","journal-title":"J Physiol Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"101877","DOI":"10.1016\/j.tice.2022.101877","article-title":"Olmesartan ameliorates cyclophosphamide-induced hemorrhagic cystitis in rats via\n                    Nrf2\/HO-1 signaling pathway","volume":"78","author":"B M Mohamed","year":"2022","journal-title":"Tissue and Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1080\/21655979.2021.1997090","article-title":"The protective effects of Olmesartan against interleukin-29 (IL-29)-induced type\n                    2 collagen degradation in human chondrocytes","volume":"13","author":"Y Liu","year":"2022","journal-title":"Bioengineered."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11095-021-03126-5","article-title":"Olmesartan niosomes ameliorates the Indomethacin-induced gastric ulcer in rats:\n                    Insights on MAPK and Nrf2\/HO-1 signaling pathway","volume":"38","author":"A A Sallam","year":"2021","journal-title":"Pharm Res"},{"key":"ref19","first-page":"1","volume":"28","author":"I M Ozguler","year":"2021","journal-title":"The effectiveness of olmesartan on inflammation at cardiopulmonary\n                    bypass"},{"key":"ref20","first-page":"404","article-title":"The Anti-Apoptotic, Anti-Inflammatory And Anti-Oxidant Effects Of Olmesartan On\n                    Renal I\/R Injury In Male Rat Model","volume":"12","author":"A M Hameed","year":"2021","journal-title":"Sys Rev Pharm"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.taap.2018.12.020","article-title":"Olmesartan ameliorates chemically-induced ulcerative colitis in rats via\n                    modulating NF\u03baB and Nrf-2\/HO-1 signaling crosstalk","volume":"364","author":"S Saber","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e05641","DOI":"10.1016\/j.heliyon.2020.e05641","article-title":"Molecular docking, molecular dynamics, and in vitro studies reveal the potential\n                    of angiotensin II receptor blockers to inhibit the COVID-19 main protease","volume":"6","author":"R Alnajjar","year":"2020","journal-title":"Heliyon"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9841-8_1","article-title":"Diabetic nephropathy: an overview","volume":"2067","author":"M K Sagoo","year":"2020","journal-title":"Diabetic Nephropathy: Methods protoco"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic Nephropathy: Diagnosis, Prevention, and Treatment","volume":"28","author":"J L Gross","year":"2005","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ncpendmet0894","article-title":"The pathogenesis of diabetic nephropathy","volume":"4","author":"S Dronavalli","year":"2008","journal-title":"Nat Rev Endocrinol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"175117","DOI":"10.1016\/j.ejphar.2022.175117","article-title":"Role of olmesartan in ameliorating diabetic nephropathy in rats by targeting the\n                    AGE\/PKC, TLR4\/P38-MAPK and SIRT-1 autophagic signaling\n                    pathways","volume":"928","author":"N M El-Nasr","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.2147\/DDDT.S217826","article-title":"Olmesartan medoxomil, an angiotensin II-receptor blocker, ameliorates renal\n                    injury Indb\/db mice","volume":"13","author":"Y Zhu","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s13730-019-00379-3","article-title":"Two cases of advanced stage rapidly progressive diabetic nephropathy effectively\n                    treated with combination therapy including RAS blocker, GLP-1 receptor agonist\n                    and SGLT-2 inhibitor","volume":"2","author":"J Morino","year":"2019","journal-title":"CEN Case Reports"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.3390\/ijms20153843","article-title":"Olmesartan attenuates kidney fibrosis in a murine model of Alport syndrome by\n                    suppressing tubular expression of TGF\u03b2","volume":"20","author":"S H Suh","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref30","first-page":"344","article-title":"Beneficial Effect on Diabetic Nephropathy by Monotherapy as Well as their\n                    Combinations Therapy","volume":"11","author":"S Vohra","year":"2023","journal-title":"J Coast Life Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1159\/000452588","article-title":"Olmesartan prevents microalbuminuria in db\/db diabetic mice through\n                    inhibition of angiotensin II\/p38\/SIRT1-induced podocyte\n                    apoptosis","volume":"41","author":"J Gu","year":"2016","journal-title":"Kidney Blood Press. Res"},{"key":"ref32","first-page":"562","article-title":"Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic\n                    variables and vascular structural properties in streptozotocin-induced diabetic\n                    rats","volume":"124","author":"H F Song","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"ref33","first-page":"379","article-title":"Olmesartan blocks advanced glycation end products-induced vcam-1 gene expression\n                    in mesangial cells by restoring Angiotensin-converting enzyme 2 level","volume":"46","author":"Y Ishibashi","year":"2014","journal-title":"Horm Metab Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1021\/acschemneuro.0c00775","article-title":"Olmesartan Prevents Oligomerized Amyloid \u03b2 (A\u03b2)-Induced Cellular\n                    Senescence in Neuronal Cells","volume":"12","author":"J Wang","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1007\/s12035-020-01964-9","article-title":"The brain AT2R\u2014a potential target for therapy in Alzheimer\u2019s\n                    disease and vascular cognitive impairment: A comprehensive review of clinical\n                    and experimental therapeutics","volume":"57","author":"H A Ahmed","year":"2020","journal-title":"Mol Neurobiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2174\/1871527315666161003165855","article-title":"Multiple targets for the management of Alzheimer\u2019s disease","volume":"15","author":"S S Ahmad","year":"2016","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref37","first-page":"1","article-title":"The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor\n                    blockers and cognitive decline in Alzheimer\u2019s disease: the importance of\n                    blood-brain barrier penetration and APOE \u03b54 carrier status","volume":"13","author":"M Ouk","year":"2021","journal-title":"Alzheimer's Res Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/HYPERTENSIONAHA.109.138586","article-title":"Angiotensin receptor blocker prevented \u03b2-amyloid-induced cognitive\n                    impairment associated with recovery of neurovascular coupling","volume":"54","author":"S Takeda","year":"2009","journal-title":"Hypertension"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1440-1681.13738","article-title":"Angiotensin receptor blockade with olmesartan alleviates brain pathology in\n                    obese OLETF rats","volume":"50","author":"C J Rodriguez-Ortiz","year":"2023","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.exger.2016.11.012","article-title":"Chronic kidney disease accelerates cognitive impairment in a mouse model of\n                    Alzheimer's disease, through angiotensin II","volume":"87","author":"T Nakagawa","year":"2017","journal-title":"Exp Gerontol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2014.03.030","article-title":"Differential effects of angiotensin II receptor blockers on A\u03b2\n                    generation","volume":"567","author":"J Liu","year":"2014","journal-title":"Neurosci Lett"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","article-title":"Interactions of coronaviruses with ACE2, angiotensin II, and RAS\n                    inhibitors\u2014lessons from available evidence and insights into\n                    COVID-19","volume":"43","author":"H Kai","year":"2020","journal-title":"Hypertens Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system Inhibitors in patients with\n                    Covid-19","volume":"382","author":"M Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"16843","DOI":"10.1038\/s41598-021-96294-8","article-title":"Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting\n                    enzyme 2, in mouse models of chronic kidney disease","volume":"11","author":"S Tsukamoto","year":"2021","journal-title":"Sci Rep"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1187818","DOI":"10.3389\/fphar.2023.1187818","article-title":"Olmesartan alleviates SARS-CoV-2 envelope protein induced renal fibrosis by\n                    regulating HMGB1 release and autophagic degradation of TGF-\u03b21","volume":"14","author":"S Zhou","year":"2023","journal-title":"Front pharmacol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.heliyon.2020.e05641","article-title":"Molecular docking, molecular dynamics, and in vitro studies reveal the potential\n                    of angiotensin II receptor blockers to inhibit the COVID-19 main protease","volume":"6","author":"R Alnajjar","year":"2020","journal-title":"Heliyon"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijcard.2016.06.115","article-title":"A literature review to evaluate the clinical and economic value of olmesartan\n                    for the treatment of hypertensive patients","volume":"221","author":"G Kourlaba","year":"2016","journal-title":"Int J Cardiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"107230","DOI":"10.1016\/j.carpath.2020.107230","article-title":"The effect of olmesartan on aortic intimal thickening after balloon injury\n                    through Apelin\/APJ","volume":"49","author":"Y Li","year":"2020","journal-title":"Cardiovasc Pathol"},{"key":"ref49","first-page":"177","article-title":"Olmesartan medoxomil for the treatment of hypertension in children and\n                    adolescents","volume":"7","author":"G Tocci","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1007\/s12325-020-01404-z","article-title":"Real-World Effectiveness and Safety of a Single-Pill Combination of\n                    Olmesartan\/Amlodipine\/Hydrochlorothiazide in Korean Patients\n                    with Essential Hypertension (RESOLVE): A Large, Observational, Retrospective,\n                    Cohort Study","volume":"37","author":"S J Park","year":"2020","journal-title":"Adv Ther"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/11536710-000000000-00000","article-title":"Efficacy and safety of olmesartan medoxomil 40 mg\/hydrochlorothiazide\n                    12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in\n                    patients with moderate to severe hypertension: a randomized, double-blind,\n                    parallel-group, multicentre, multinational, phase III study","volume":"30","author":"R Fogari","year":"2010","journal-title":"Clin Drug Investig"},{"key":"ref53","first-page":"66","article-title":"Effectiveness of Olmesartan on Blood Pressure Control in Hypertensive Patients\n                    in India: A Real World, Retrospective, Observational Study from Electronic\n                    Medical Records","volume":"68","author":"M Y Khan","year":"2020","journal-title":"J Assoc Physicians India"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/4487393","article-title":"The Clinical Efficacy of ClopidogrelBisulfate Tablets Combined with Olmesartan\n                    Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II\n                    Type 1 Receptor Level on Prognosis","volume":"2021","author":"J Yu","year":"2021","journal-title":"Comput Math Methods Med"},{"volume-title":"In: StatPearls [Internet]","year":"2023","author":"C C Kerndt","key":"ref55"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"ROADMAP Trial Investigators. Olmesartan for the delay or prevention of\n                    microalbuminuria in type 2 diabetes","volume":"364","author":"H Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13098-023-00987-1","article-title":"Effect of olmesartan and amlodipine on serum angiotensin-(1-7) levels and kidney\n                    and vascular function in patients with type 2 diabetes and hypertension","volume":"15","author":"K Kim","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"ORIENT study investigators. Effects of olmesartan on renal and cardiovascular\n                    outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised,\n                    placebo-controlled study","volume":"54","author":"E Imai","year":"2011","journal-title":"Diabetologia"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajh\/hpu197","article-title":"Neuroprotective Effects of Angiotensin Receptor Blockers","author":"S Villapol","year":"2015","journal-title":"Am J Hypertens"},{"key":"ref61","first-page":"1","article-title":"Design and rationale for a comparison study of Olmesartan and Valsartan On\n                    myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial:\n                    study protocol for a randomized controlled trial","volume":"23","author":"S Jo","year":"2022","journal-title":"Trials."},{"key":"ref66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2019\/9830295","article-title":"Effect of nebivolol and olmesartan on 24-hour brachial and aortic blood pressure\n                    in the acute stage of ischemic stroke","volume":"2019","author":"E Georgianou","year":"2019","journal-title":"Int J Hypertens"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3390\/jcm11020350","article-title":"A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial\n                    Evaluating the Efficacy and Safety of Olmesartan\/Amlodipine plus\n                    Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and\n                    Dyslipidemia: A LEISURE Study","volume":"11","author":"S H Jo","year":"2022","journal-title":"J Clin Med"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2244-3136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:12:51Z","timestamp":1730823171000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2244-3136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":58,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,3,1]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2244-3136","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"type":"print","value":"2194-9379"},{"type":"electronic","value":"2194-9387"}],"subject":[],"published":{"date-parts":[[2024,2,13]]}}}